REVERSE-IT/PhaseBio Pharmaceuticals
PhaseBio introduces REVERSE-IT [https://reverse-it-trial.com/] (Rapid and SustainEd ReVERSal of TicagrElor—Intervention Trial), the pivotal Phase 3 trial designed to study reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who present with uncontrolled major or life-threatening bleeding or who require surgery or an invasive procedure (NCT04286438). For more information on REVERSE-IT, please visit https://clinicaltrials.gov/ct2/show/NCT04286438.
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases.
PhaseBio is located in Malvern, PA, and San Diego, CA.
Brands: Bentracimab